Nonalcoholic Fatty Liver Disease, Carotid Intima-Media Thickness and Lipid Profile in Epileptic Children

Abstract

Background: Sodium valporate and carbamazepine are among frequent medications utilized for seizure control in children. Several adverse effects such as fatty liver disease, lipid profile changes and increased Intima-Media Thickness (IMT) were reported among cases who were treated with these medications.

Methods: Here we assessed 38 children (under 18) who were treated by sodium valporate and carbamazepine for at least six months for developing adverse effects including fatty liver disease, lipid profile changes and increased IMT. Cases who were treated with two or more antiepileptic-drugs or treated less than six months with each of drugs were excluded. Fasting venous blood sample drawn andradiologic evaluation of liver and both carotid arteries by two independent individuals performed.

Results: We found fatty liver disease in five patients who were treated with sodium valporate and lower White Blood Cell (WBC) count in carbamazepine group. Lipid profiles and IMT of both carotid arteries were not significantly different between groups.

Conclusion: Children who are treated with sodium valproate would be better to be carefully assessed by sonographic modalities for developing fatty liver as an adverse effect of the drug.



J Neurol Res. 2011;1(3):105-108
doi: https://doi.org/10.4021/jnr40w